Scientific Reports (Apr 2022)

2 deoxy-D-glucose augments the mitochondrial respiratory chain in heart

  • Irati Aiestaran-Zelaia,
  • María Jesús Sánchez-Guisado,
  • Marina Villar-Fernandez,
  • Mikel Azkargorta,
  • Lucia Fadon-Padilla,
  • Uxoa Fernandez-Pelayo,
  • Diego Perez-Rodriguez,
  • Pedro Ramos-Cabrer,
  • Antonella Spinazzola,
  • Félix Elortza,
  • Jésus Ruíz-Cabello,
  • Ian J. Holt

DOI
https://doi.org/10.1038/s41598-022-10168-1
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 9

Abstract

Read online

Abstract 2-Deoxy-D-glucose (2DG) has recently received emergency approval for the treatment of COVID-19 in India, after a successful clinical trial. SARS-CoV-2 infection of cultured cells is accompanied by elevated glycolysis and decreased mitochondrial function, whereas 2DG represses glycolysis and stimulates respiration, and restricts viral replication. While 2DG has pleiotropic effects on cell metabolism in cultured cells it is not known which of these manifests in vivo. On the other hand, it is known that 2DG given continuously can have severe detrimental effects on the rodent heart. Here, we show that the principal effect of an extended, intermittent 2DG treatment on mice is to augment the mitochondrial respiratory chain proteome in the heart; importantly, this occurs without vacuolization, hypertrophy or fibrosis. The increase in the heart respiratory chain proteome suggests an increase in mitochondrial oxidative capacity, which could compensate for the energy deficit caused by the inhibition of glycolysis. Thus, 2DG in the murine heart appears to induce a metabolic configuration that is the opposite of SARS-CoV-2 infected cells, which could explain the compound’s ability to restrict the propagation of the virus to the benefit of patients with COVID-19 disease.